<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316144</url>
  </required_header>
  <id_info>
    <org_study_id>Junshi-JS001-011</org_study_id>
    <nct_id>NCT03316144</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics &amp; Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma</brief_title>
  <official_title>A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety and tolerability of JS-001 in subjects with&#xD;
      recurrent malignant lymphoma, and to evaluate its preliminary efficacy.&#xD;
&#xD;
      The secondary objectives are to: 1) characterize the single-dose and multi-dose&#xD;
      pharmacokinetic (PK) profile of JS-001, 2) characterize the immunogenicity of JS-001; 3)&#xD;
      assess the dose-efficacy relationship of JS-001 single agent, and 4) preliminarily evaluate&#xD;
      biomarkers associated with the efficacy of JS-001.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation analysis of PD-L1 expression of tumor</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by irRC and RECIST 1.1</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Malignant Lymphoma</condition>
  <arm_group>
    <arm_group_label>1 mg/kg Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/kg Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.</description>
    <arm_group_label>1 mg/kg Toripalimab</arm_group_label>
    <arm_group_label>10 mg/kg Toripalimab</arm_group_label>
    <arm_group_label>3 mg/kg Toripalimab</arm_group_label>
    <other_name>JS001, TAB001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to sign Informed Consent;&#xD;
&#xD;
          -  Re-entry into the study is allowed with a second informed consent;&#xD;
&#xD;
          -  Willing to provide blood sample for biomarker analysis(mandatory). The tissue sample&#xD;
             is optional;&#xD;
&#xD;
          -  A diagnosis of an advanced malignant tumor confirmed by histology or cytology&#xD;
             (including typical Hodgkin's lymphoma and B cell source non-hodgkin's lymphoma);&#xD;
&#xD;
          -  No standard of care for the patient;&#xD;
&#xD;
          -  At least 1 measurable lesion;&#xD;
&#xD;
          -  Aged 18-65 years;&#xD;
&#xD;
          -  Anticipated life expectancy of at least 6 months;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;&#xD;
&#xD;
          -  At least 4 weeks elapsed since receiving systemic chemotherapy;&#xD;
&#xD;
          -  At least 4 weeks elapsed since receiving definite radiotherapy;&#xD;
&#xD;
          -  At least 2 weeks since the last dose of systemic steroid therapy (&gt;10 mg/day&#xD;
             prednisone or equivalent);&#xD;
&#xD;
          -  At least 4 weeks since receiving anti-cancer biotherapy;&#xD;
&#xD;
          -  Recovered from previous treatment related adverse reaction; willing to use an&#xD;
             acceptable contraceptive method;&#xD;
&#xD;
          -  A negative pregnancy test for female subjects of childbearing potential;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis;&#xD;
&#xD;
          -  Known history of another primary solid tumor, unless the participant has undergone&#xD;
             potentially curative therapy with no evidence of that disease for 2 years, or&#xD;
             underwent successful definitive resection of basal or squamous cell carcinoma of the&#xD;
             skin, or in situ cervical cancer;&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease.Autoimmune diseases caused by lymphoma&#xD;
             are not included in this list;&#xD;
&#xD;
          -  Patients who have had car-T cell therapy&#xD;
&#xD;
          -  Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-cytotoxic T-lymphocyte&#xD;
             antigen 4 (CTLA-4) blocking antibodies;&#xD;
&#xD;
          -  Significant medical disease;&#xD;
&#xD;
          -  Active infection;&#xD;
&#xD;
          -  Active tuberculosis or history of tuberculosis with one year;&#xD;
&#xD;
          -  Infection of Human immunodeficiency virus (HIV);&#xD;
&#xD;
          -  A complication requiring immune-suppression;&#xD;
&#xD;
          -  Received a live vaccine within 4 weeks prior to first dose of study drug pleural or&#xD;
             abdominal effusion with symptoms;&#xD;
&#xD;
          -  Drug or alcohol abuse (for subjects in the pharmacokinetic cohorts) ; evidence of&#xD;
             interstitial lung disease;&#xD;
&#xD;
          -  Active hepatitis B or C, or with significant risk of hepatitis reactivation;&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to monoclonal&#xD;
             antibodies or drugs chemically related to the study drug. History of serious&#xD;
             hypersensitivity reaction or serious hepatotoxicity related to any drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junyuan Qi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Diseases Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>check point inhibitor</keyword>
  <keyword>PD-1 antibody</keyword>
  <keyword>phase 1 trial</keyword>
  <keyword>Malignant Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

